About one-quarter of all tumors are considered to be hormone-sensitive: different forms of hematologic malignancies belong to this group, since treatment with corticosteroids plays an important antitumor role in these diseases. Hormone responsiveness, which was strikingly demonstrated as early as 1898 by Beatson, who performed the first oophorectomy for breast cancer, represents an intringuing biologic phenomenon, since it opposes the often held dogma of a complete autonomy of the tumor growth. This may be more understandable today, now that our biologic comprehension of oncogenesis is rapidly evolving.
KeywordsBreast Cancer Clin Oncol Endocrine Treatment Advanced Breast Cancer Endometrial Carcinoma
Unable to display preview. Download preview PDF.
- Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4: 186–193Google Scholar
- Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M, Cappelaere P (1985) Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mgandl g/day. Eur J Cancer Clin Oncol 21:1153–1158PubMedCrossRefGoogle Scholar
- Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Am J Clin Oncol 4: 237–248Google Scholar
- Lippman ME, Chabner BA (1986) Editorial overview. NCI Monograph 1: 29–34Google Scholar
- McClelland RA, Berger U, Miller LS et al. (1986) Immunocyto-chemical assay for oestrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res [Suppl] 46: 4241–4243Google Scholar
- Robin PE, Dalton GA (1977) The role of major endocrine ablation. In: Stoll BA, (ed) Breast cancer management - early and late. Year Book, Chicago, pp 147–156Google Scholar
- Rose C, Mouridsen HT(1984) Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res 91: 230–242Google Scholar